Apr 29, 2021
Evolus to Participate in the 7th Annual Truist Securities Life Sciences Summit
|Event:||7th Annual Truist Securities Life Sciences Summit|
|Format:||Fireside Chat & 1x1 Meetings|
|Location:||Evolus Live Fireside Chat|
An audio webcast of Evolus’ fireside chat will be available on the investor relations section of Evolus’ website at investors.evolus.com. Replay of the webcast will be available for 90 days after the date of the presentation.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.
Jeuveau® is a registered trademark of
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Senior Vice President